Posted by Michael Wonder on 14 Sep 2022
Lupin receives Health Canada approval for Rymti (biosimilar etanercept)
13 September 2022 - Rymti is Lupin’s biosimilar etanercept approved for all indications of the reference product.
Lupin Pharmaceuticals announced today that Health Canada has approved Rymti, its biosimilar to Enbrel (etanercept), for use in Canada.
